Aldevron has named Kevin Ballinger as chief executive officer, effective July 13, 2020, and Aldevron’s co-founder, Michael Chambers, has been named executive chairman of the board. Chambers initiated the transition to allow him to “focus on innovation, corporate strategy and working with clients and industry thought leaders to develop new technologies that enable genetic medicine.” Ballinger will assume day-to-day operational leadership of Aldevron, facilitating the company’s rapid growth.   Bal...